₹195.84
−4.86%NSE close, 16 Nov 2026
+46.86%
Sun Pharma Advanced Research Company is a small cap company in the Healthcare sector, listed on NSE under the symbol SPARC. At ₹195.84 a share, the market values the whole company at ₹6,355 crore.
In FY26, it reported sales of ₹1,879 crore and a net profit of ₹1,556 crore, an operating margin of 85.1%. Over the last three years, sales grew 139.2% a year.
The market values the company at 3.9 times its profit over the last twelve months and 4.41 times its book value; its return on equity is 113.4% and it has almost no borrowings.
Promoters hold 65.67% of the shares. Foreign institutions hold 3.75%, and domestic institutions, mutual funds among them, 0.11%.
Over the past year the share price has risen 45.5%, and it is 32.2% below its 52-week high.
Companies of a similar size in the same sector include Strides Pharma Science, Aarti Pharmalabs, Healthcare Global Enterprises and Thyrocare Technologies.
₹ crore. Consolidated figures.
The same sector (Healthcare), nearest in size.
| Company | Price | Market cap | P/E | ROE | Sales growth | 1Y |
|---|---|---|---|---|---|---|
| Sun Pharma Advanced Research Company | ₹195.84 | ₹6,355 cr | 3.9 | 113.4% | +282.10% | +45.52% |
| Strides Pharma Science | ₹986.10 | ₹9,089 cr | 14.7 | 18.1% | +17.10% | +2.78% |
| Aarti Pharmalabs | ₹986.75 | ₹8,948 cr | 35.4 | 11.2% | +45.90% | +16.93% |
| Healthcare Global Enterprises | ₹568.20 | ₹8,483 cr | 750.7 | 0.8% | +13.10% | −24.77% |
| Thyrocare Technologies | ₹509.65 | ₹8,112 cr | 56.3 |
Receipt of No-objection letters from the Stock Exchanges for Reclassification of Promoter Group
Significant increase in volume has been observed in Sun Pharma Advanced Research Company Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is…
Significant increase in volume has been observed in Sun Pharma Advanced Research Company Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is…
Monitoring Agency Report for the quarter ended September 30, 2026.
Written from the company's filings with NSE and the exchanges' daily prices. For information only, not a recommendation to buy, sell or hold any security.
| Dec 2025 |
|---|
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 13.9 | 16.6 | 16.8 | 12.9 | 14.9 | 27.2 | 9.6 | 7.9 | 8.5 | 1,853 | 39.9 | 30.0 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 116 | 122 | 110 | 116 | 88.6 | 80.4 | 61.7 | 73.6 | 65.1 | 80.0 | 73.9 | 75.6 |
| Operating profit | −103 | −106 | −93.4 | −103 | −73.7 | −53.2 | −52.1 | −65.7 | −56.6 | 1,773 | −34.0 | −45.6 |
| Operating margin | -740.4% | -639.1% | -555.4% | -800.2% | -494.2% | -195.6% | -540.2% | -836.1% | -670.3% | 95.7% | -85.2% | -151.9% |
| Other income | 6.4 | 4.4 | 1.6 | 0.0 | 0.2 | 0 | 9.1 | 0.0 | 0 | 1.8 | 23.7 | 23.6 |
| Interest | 0.3 | 0.9 | 0.6 | 1.1 | 2.8 | 4.5 | 6.2 | 7.5 | 8.8 | 11.6 | 8.1 | 0.1 |
| Depreciation | 3.2 | 3.1 | 3.1 | 3.2 | 3.1 | 3.0 | 2.7 | 2.6 | 2.6 | 2.4 | 2.2 | 2.2 |
| Profit before tax | −99.7 | −105 | −95.5 | −107 | −79.4 | −60.7 | −51.8 | −75.8 | −80.4 | 1,761 | −20.7 | −24.3 |
| Tax | 0 | 0.4 | 0.4 | 0.2 | 0.1 | −0.9 | 0.1 | 0.1 | 0.1 | −0.4 | 0.1 | 0.1 |
| Net profit | −99.3 | −106 | −95.9 | −107 | −79.5 | −60.2 | −51.9 | −75.9 | −80.4 | 1,763 | −20.8 | −26.0 |
| EPS (₹) | -3.07 | -3.26 | -2.96 | -3.31 | -2.45 | -1.84 | -1.60 | -2.34 | -2.48 | 54.27 | -0.64 | -0.75 |
₹ crore, financial years to March.
| Line | FY19 S | FY20 S | FY21 S | FY22 S | FY23 S | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Sales | 183 | 76.8 | 253 | 137 | 239 | 71.8 | 1,879 |
| Expenses | 334 | 387 | 388 | 324 | 453 | 395 | 280 |
| Operating profit | −151 | −310 | −135 | −187 | −214 | −323 | 1,599 |
| Operating margin | -82.7% | -403.6% | -53.4% | -136.1% | -89.7% | -450.2% | 85.1% |
| Other income | 13.5 | 9.8 | 5.4 | 6.8 | 11.0 | 1.8 | 11.0 |
| Interest | 0.1 | 2.7 | 10.7 | 13.3 | 7.6 | 9.0 | 34.1 |
| Depreciation | 7.6 | 9.5 | 10.9 | 10.2 | 11.8 | 12.4 | 10.2 |
| Profit before tax | −145 | −312 | −151 | −203 | −223 | −343 | 1,553 |
| Tax | 0 | 0 | 0 | 0 | 0 | −0.3 | −0.2 |
| Net profit | −145 | −312 | −151 | −203 | −223 | −343 | 1,556 |
| EPS (₹) | -5.69 | -11.92 | -5.77 | -7.73 | -7.73 | -10.55 | 47.86 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | −208 | −360 | −239 | 1,685 |
| From investing | −29.2 | 158 | −23.5 | −1,268 |
| From financing | 229 | 199 | 261 | −416 |
| Spent on fixed assets | −32.7 | −10.3 | −23.8 | −2.2 |
| Free cash flow | −241 | −371 | −263 | 1,683 |
Margins, returns, debt, tax and cash.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Net margin | -79.5% | -406.7% | -59.7% | -148.2% | -93.2% | -477.5% | 82.8% |
| Operating margin | -82.7% | -403.6% | -53.4% | -136.1% | -89.7% | -450.2% | 85.1% |
| Return on equity | – | – | – | – | -43.4% | – | 116.2% |
| Return on capital employed | – | – | – | – | -41.9% | – | 83.8% |
| Return on assets | – | – | – | – | -26.8% | -102.1% | 71.7% |
| Debt to equity | – | – | – | – | 0.00 | – | 0.42 |
| Interest coverage | -1,614.90 | -116.00 | -13.20 | -14.30 | -28.20 | -36.90 | 46.50 |
| Debt to assets | – | – | – | – | 0.00 | 0.77 | 0.26 |
| Current ratio | – | – | – | – | 2.54 | 0.07 | 2.47 |
| Quick ratio | – | – | – | – | 2.54 | 0.07 | 2.47 |
| Cash ratio | – | – | – | – | 0.00 | 0.01 | 0.00 |
| Asset turnover | – | – | – | – | 0.29 | 0.21 | 0.87 |
| Fixed asset turnover | – | – | – | – | 2.27 | 0.73 | 22.06 |
| Receivables turnover | – | – | – | – | 7.30 | 4.50 | 227.20 |
| Gross margin | – | – | – | – | – | 67.8% | – |
| Cash from operations to profit | – | – | – | – | – | – | -15.0% |
| 26.1% |
| +25.10% |
| +15.46% |
| Suven Life Sciences | ₹268.90 | ₹7,598 cr | n/a | -84.2% | +30.40% | +39.45% |
|---|
| Nephrocare Health Services | ₹642.00 | ₹6,456 cr | 50.4 | 10.8% | n/a | n/a |
|---|
| Senores Pharmaceuticals | ₹1,147.80 | ₹5,286 cr | 38.2 | 13.8% | +18.90% | +42.61% |
|---|
| Supriya Lifescience | ₹622.30 | ₹5,008 cr | 28.3 | 14.3% | +3.20% | −20.15% |
|---|
The unaudited financial results for the quarter and half year ended September 30, 2026.
Update on Litigation.
Filing of Application for Reclassification with Stock Exchanges
Proceedings of Annual General Meeting held on August 10, 2026
Monitoring Agency Report for the quarter ended June 30, 2026.
Outcome of Board Meeting held on August 10, 2026.
The Unaudited Financial Results for the quarter ended June 30, 2026.
Receipt of requests for reclassification of shareholder category
Notice of Annual General Meeting to be held on August 10, 2026 along with the Annual Report for FY 2025-26
Change in Director(s) of the company.
Intimation of the 21st Annual General Meeting of the Company